ABSTRACT OBJECTIVES This study assessed outcomes in patients in whom subcutaneous implantable cardioverter-defibrillator (S-ICD) therapy was continued after implantation-related complications, in order to avoid conversion to transvenous ICD therapy.
and convert ventricular arrhythmias (2, 6, 7) . 
RESULTS
PATIENT CHARACTERISTICS. A total of 123 patients (56.9% male) who received an S-ICD were included in Brouwer et al.
Management of S-ICD Complications F E B R U A R Y 2 0 1 6 : 8 9 -9 6 the current analysis. to 96.3%), respectively ( Figure 1 ).
There were a total of 8 infectious complications that required surgical intervention: 5 cases of device infection 4.6% (95% CI: 0.6% to 8.5%) and 3 cases of pocket erosion 3.6% (95% CI: 0.0% to 7.6%). Table 2 displays the characteristics of patients with a complication.
Complications not related to the implant procedure that were excluded from the analysis consisted of 1 pulse generator malfunction, 1 case of oversensing, and 1 fatal case of lead endocarditis of a concomitant pacemaker in a patient with congenital heart disease, who was deemed inoperable. When these complications were included, the rate at 2-year follow-up was 11.8% (95% CI: 5.2% to 18.0%).
MANAGEMENT OF INFECTION-RELATED COMPLICATIONS.
All 5 This management proved successful in 1 patient. In the other 2 patients, signs of pocket erosion recurred at 245 and 270 days after repositioning. In both patients, the system was extracted to allow full recovery, and they were fitted with a WCD for a period of 3 months. After this period, both patients underwent successful reimplantation, one in the same subcutaneous position and the other in a deeper subserratus anterior muscle (SAM) position. All 3 patients were free from complications up to the last follow-up visit more than 1 year after reimplantation.
Predictors of infection in transvenous systems
were assessed with univariate logistic regression models, but age, diabetes, concomitant transvenous device, infection of previous transvenous device, and anticoagulation were found not to be significantly associated with S-ICD infection in this small cohort (data not shown).
MANAGEMENT OF ACUTE NONINFECTIOUS COMPLICATIONS.
Patient #9 suffered an inappropriate shock approxi- E n t i r e l y s u b m u s c u l a r i m p l a n t a t i o n o f t h e p u l s e g e n e r a t o r . In 3 patients who did not tolerate the subcutaneous position, the pulse generator was reimplanted directly under the SAM. The (95% CI: 0.6% to 8.5%), respectively (14) . This demonstrates that conversion to transvenous ICD therapy in case of an S-ICD complication is not necessary, and transvenous leads can be avoided.
In a nationwide cohort, we reported preiously that in S-ICD patients with a device infection, 4 of 7 patients were reimplanted with a transvenous ICD (9) . Although no arrhythmia episodes were treated by the WCD, we advocate this management for safety and to avoid prolonged hospitalization. 
CONCLUSIONS
In most patients with a complication, subcutaneous ICD therapy could be continued after intervention, avoiding the need to convert to a transvenous system. 
